Kazia’s Cantrixil Shows Signs of Effectiveness in Advanced Ovarian Cancer Trial

Kazia’s Cantrixil Shows Signs of Effectiveness in Advanced Ovarian Cancer Trial
Cantrixil, an investigative therapy which targets cancer cells that cause recurrence, shows promise as a treatment for ovarian cancer patients who failed at least two prior therapies, according to Australia-based Kazia Therapeutics (formerly Novogen). The treatment is being assessed alone and in combination with chemotherapy. To date, 60% of patients (three out of five) who received the

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *